Business Context and Reporting Period
Company: Black Diamond Therapeutics, Inc. (BDTX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Black Diamond is a clinical-stage oncology company developing "MasterKey" therapies targeting families of oncogenic mutations. Its lead asset, silevertinib, is a brain-penetrant, fourth-generation EGFR inhibitor currently in Phase 2 trials for non-small cell lung cancer (NSCLC) and planned for a randomized Phase 2 trial in glioblastoma (GBM) in Q2 2026. The company outlicensed its second asset, BDTX-4933, to Servier Pharmaceuticals in Q1 2025.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| License Revenue | $70,000 | $0 |
| Total Operating Expenses | $57,478 | $78,781 |
| Net Income (Loss) | $22,367 | $(69,676) |
| Cash, Cash Equivalents, and Investments | $128,700 | $98,575 |
| Accumulated Deficit | $(464,740) | $(487,107) |
| Operating Cash Flow | $29,614 | $(62,303) |
Note: The company reported a net income of $22.4 million in 2025, reversing a net loss of $69.7 million in 2024. This turnaround was driven by a $70 million upfront licensing payment and reduced operating expenses.
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $70.0 million in license revenue in 2025, compared to zero in 2024. This resulted from the global licensing agreement with Servier Pharmaceuticals for BDTX-4933, executed in March 2025.
- Expense Reduction: Total operating expenses decreased by $21.3 million (27%) to $57.5 million.
- R&D Expenses: Declined $17.8 million to $33.6 million, primarily due to the outlicensing of BDTX-4933 and operational efficiencies in the silevertinib program.
- G&A Expenses: Declined $10.9 million to $16.6 million, attributed to workforce efficiencies and corporate restructuring.
- Impairment Charges: The company recorded a $7.3 million impairment charge in 2025 related to right-of-use assets and property and equipment, primarily due to sublease terminations and modifications. No such charge was recorded in 2024.
- Liquidity: Cash and investments increased to $128.7 million as of December 31, 2025, up from $98.6 million in 2024, bolstered by the licensing upfront payment and positive operating cash flow.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Clinical Milestones: Management plans to present updated Phase 2 NSCLC data (frontline and recurrent settings) in Q2 2026. A randomized Phase 2 trial for silevertinib in newly diagnosed EGFR-altered GBM is expected to initiate in Q2 2026, with interim data anticipated in H1 2028.
- Capital Runway: Management believes current capital resources ($128.7 million) are sufficient to fund operations into the second half of 2028.
- Partnerships: The company is exploring potential partnerships for the pivotal development of silevertinib and strategic alternatives for its FGFR program (BDTX-4876).
Key Risks and Contingencies
- Development Risk: The company is heavily dependent on silevertinib. Failure to demonstrate safety/efficacy in ongoing trials or delays in enrollment could materially harm the business.
- Regulatory Risk: The company has not received FDA approval for any product. Regulatory authorities may require additional trials or reject applications.
- Financial Risk: Despite the 2025 net income, the company has an accumulated deficit of $464.7 million and expects to incur significant losses in the future. Additional funding will be required beyond 2028.
- Geopolitical/Trade: Risks include potential tariffs, supply chain disruptions, and the impact of the BIOSECURE Act on relationships with Chinese biotechnology providers.
Investor Verification Checklist
- Clinical Data Validation: Verify the upcoming Q2 2026 presentation of silevertinib Phase 2 data, specifically the Objective Response Rate (ORR) and Duration of Response (DOR) in the frontline NSCLC setting.
- Capital Adequacy: Confirm the burn rate and the sufficiency of the $128.7 million cash balance to reach the H2 2028 runway target, considering potential delays in clinical trials.
- Licensing Terms: Review the specific milestones and royalty structures in the Servier agreement for BDTX-4933 to understand future revenue potential beyond the $70 million upfront payment.
- GBM Trial Initiation: Monitor the timeline for the initiation of the randomized Phase 2 GBM trial in Q2 2026 and patient enrollment progress.
- Sublease Impact: Assess the long-term impact of the $7.3 million impairment charge and the reduction in facility footprint on future G&A expenses.